"The legislative landscape on Capitol Hill is fraught with peril as key healthcare provisions, including the renewal of Affordable Care Act subsidies and crucial government funding, face significant hurdles. Bipartisan consensus is elusive, leaving millions of Americans uncertain about their healthcare access and the stability of essential health programs."
Washington D.C. – As the legislative clock ticks down, Capitol Hill is grappling with a complex web of healthcare priorities, from the vital renewal of Affordable Care Act (ACA) subsidies to the annual appropriations process. Efforts to extend the enhanced ACA subsidies, which expired at the beginning of the year, have stalled in the Senate, while a proposed rollback of Trump-era ACA regulations also faces an uncertain future. Meanwhile, a looming government shutdown deadline intensifies negotiations over spending bills, particularly those funding the Department of Health and Human Services (HHS). Adding to the complexity are ongoing cultural and political battles over abortion access and gender-affirming care, which are increasingly intertwined with broader healthcare policy debates.
On Capitol Hill, the legislative session has been marked by a series of critical votes and ongoing negotiations that highlight deep partisan divisions and the precariousness of healthcare policy. The Senate recently rejected a Democratic proposal to extend the ACA’s enhanced subsidies for three years, a move that had previously passed the House with bipartisan support. These subsidies, crucial for making health insurance affordable for millions, expired on January 1st, leaving many individuals and families facing increased premium costs. The Senate also turned back an attempt to repeal a Trump-era regulation impacting the ACA, a regulation that, while receiving less public attention than the subsidies, could also lead to a significant number of individuals losing or dropping their health insurance coverage.
The House of Representatives, meanwhile, is operating with a razor-thin majority, a situation that has led to unexpected legislative defeats on routine matters. This fragile majority means that even a few dissenting votes can hand Democrats a victory, complicating Republican efforts to advance their agenda. The struggle to maintain legislative control has directly impacted the prospects for renewing the ACA subsidies. While 17 Republicans joined Democrats in the House to pass a bill extending the subsidies, bipartisan efforts in the Senate to secure a deal appear to be losing momentum.
Senator Bernie Moreno (R-Ohio), who had initially expressed optimism about reaching a bipartisan agreement, has seen his enthusiasm wane as negotiations have become more contentious. Disagreements persist on several fronts, including a proposal for a minimum charge for all health plans, eliminating zero-premium plans. Proponents argue this measure would curb fraud, while opponents contend it would deter low-income individuals from seeking coverage. Furthermore, the perennial debate over abortion continues to be a significant stumbling block. Disagreements on how the ACA currently addresses abortion, and how it should in the future, remain unresolved, with anti-abortion groups demanding a national ban on subsidies for any plan covering abortion—a non-starter for most Democrats.
Adding to the legislative pressure, lawmakers have just over two weeks to finalize the remaining spending bills or risk another government shutdown. While progress has been made on many fronts, the bill funding a significant portion of HHS remains a point of contention. The challenge lies in crafting a bill that can garner 60 votes in the Senate and a majority in the more conservative House. While the Hyde Amendment, which restricts federal funding for abortions, is typically renewed annually and may not be a major issue in the Labor-HHS appropriations bill, there is a divergence in priorities. Many Democrats and some Republicans in the Senate advocate for restoring funding to programs that HHS has cut, a sentiment not widely shared by House Republicans. This disparity raises questions about whether a comprehensive deal can be reached or if another continuing resolution will be necessary, extending the uncertainty for these critical health programs.
Optimism regarding the spending bills appears to be higher than for the ACA subsidy deal, though significant disagreements persist, particularly outside the healthcare arena. Immigration and foreign policy are expected to be major battlegrounds. Within healthcare, efforts to restore funding for programs previously slashed by the Trump administration have seen some Republican support, as these initiatives often impact their districts and constituents. However, the administration’s approach to appropriated funds has also come under scrutiny, with questions arising about whether Congress’s appropriations are treated as binding law or mere suggestions.
Amidst the legislative deadlock, a bipartisan health package that narrowly missed passage at the end of 2024 is being revisited. This package, which includes reforms for pharmacy benefit managers (PBMs), changes to hospital outpatient payments, and continued funding for community health centers, was stripped from a year-end spending bill due to concerns about its overall size. Advocates had pledged to prioritize its passage in the new year, but the path forward remains uncertain, especially given the broader legislative challenges. While the PBM reforms have been discussed for years, particularly since the Trump administration, their eventual enactment is still met with caution.
The expiration of enhanced ACA subsidies is already having an impact on enrollment figures. Sign-ups on the federal marketplace are down by approximately 1.5 million compared to the previous enrollment period, and this is before most individuals have had to pay their first premium. States managing their own marketplaces are also reporting increased coverage drop-offs or shifts to less expensive plans. The early numbers, while potentially lower than some predictions, suggest that many individuals may have enrolled in anticipation of a potential subsidy renewal. However, it is likely that most individuals are not closely following the intricacies of legislative negotiations on Capitol Hill. The reality of increased costs may not fully manifest until individuals begin receiving their first bills. Notably, some states are implementing their own funding initiatives to support individuals facing these shortfalls, showing positive enrollment trends in those specific markets and potentially encouraging other states to follow suit.
The underlying issue of healthcare affordability remains a persistent challenge. Recent data reveals that total national health expenditures grew by 7.2% in 2024, reaching $5.3 trillion, or 18% of the nation’s GDP. This increase underscores that rising insurance premiums are not solely attributable to the ACA but are linked to broader escalations in healthcare spending. The ACA has undeniably improved the affordability of insurance for millions, but the fundamental burden of high healthcare costs has not been resolved and may be worsening. The sheer scale of these expenditures, even if sustained over many years, points to an economic model that, while persistent, is financially taxing for individuals and the nation. The question of where this vast sum of money is allocated—hospitals, drug companies, physicians—remains a critical point of discussion, particularly as many entities within the healthcare sector claim financial constraints.
The debate over abortion access continues to cast a long shadow over healthcare policy. A Senate health committee hearing focused on the safety of mifepristone, the abortion pill, highlighted the ongoing efforts by conservatives to restrict access. This hearing, held amidst the backdrop of the March for Life, underscored the frustration among conservative lawmakers and activist groups regarding the perceived lack of action on their priority of restricting abortion pills, which constitute the majority of abortions performed today. The broader goal remains to outlaw abortion entirely, with abortion pills serving as a primary target.
Testimony from a Louisiana attorney general revealed a key motivation: despite state abortion bans, abortions are reportedly increasing due to the availability of abortion pills. This observation directly contradicts the anticipated outcome of overturning Roe v. Wade and emphasizes the growing role of medication abortion, often accessed via telemedicine. This trend is present in both states with abortion bans and those where it remains legal, with telemedicine offering a more convenient and potentially cheaper option for many. Consequently, a significant demand from conservative groups is to ban telemedicine for abortion pills and reinstate in-person dispensing requirements, a move that would curtail access nationwide. Ultimately, the most sought-after outcome is the removal of abortion pills from the market altogether.
However, a recent peer-reviewed study published in the Journal of the American Medical Association (JAMA) analyzed FDA documents and found that, over the past decade, the agency has consistently followed its scientists’ evidence-based recommendations regarding mifepristone’s availability, with only one exception occurring during the Trump administration. This evidence suggests that mifepristone is safe and effective, with a low rate of serious complications, supported by numerous studies and millions of women’s experiences globally. Despite this scientific consensus, opposition to the pills is often framed not by safety concerns but by their intended purpose—to end a pregnancy. This perspective suggests that the focus on complication rates is a tactic within a broader arsenal aimed at curbing access, rather than a primary driver of the opposition.
While high-profile anti-abortion actions like Senate hearings gain attention, legal challenges supporting abortion rights are still prevailing in lower courts. A lawsuit filed by the ACLU and the National Family Planning and Reproductive Health Association against the Trump administration was dropped after the administration quietly restored funding to Planned Parenthood and other family planning organizations. This restoration of Title X funding, previously withheld, addresses funds appropriated by Congress but not disbursed. However, this does not impact the larger Medicaid cuts enacted the previous summer, which represent a far greater financial reduction for family planning services. The conflation of these different funding streams by some conservatives has led to accusations of the administration violating congressional law. The restoration of Title X funding, while a positive development, came too late for some clinics that had already closed, and the reimbursement model means that closed facilities cannot reopen with this funding.
Beyond abortion, other cultural war issues are emerging in the healthcare sphere. The Supreme Court heard arguments in a case challenging state laws barring transgender athletes from competing in women’s sports. Early indications suggest a likelihood that the majority of justices may uphold these bans. Concurrently, the House passed a bill criminalizing gender-affirming care for minors nationwide, while proposed HHS regulations aim to achieve a similar effect by barring hospitals from providing such care to minors or risk losing Medicare and Medicaid funding. Additionally, an HHS declaration that gender-affirming care "does not meet professionally recognized standards of health care" could exclude practitioners from federal health programs. These actions raise concerns about public support for effectively ending gender-affirming care for minors, as much of the public discourse focuses on surgical interventions rather than less invasive treatments like puberty blockers and hormone therapy.
The narrative surrounding gender-affirming care often emphasizes surgery, which is a less common scenario for minors. Opponents have effectively framed the issue around this more extreme possibility, overshadowing the reality that much of this care involves hormone treatment and puberty blockers. These treatments are not permanent and can be reversed, acting as a temporary pause in puberty. While questions remain about optimal age and duration of treatment, and potential side effects like bone density loss, experts in endocrinology and psychology highlight the significant benefits for minors experiencing gender dysphoria. The prevailing sentiment among medical professionals is that this care is not only safe but also beneficial for adolescents struggling with their gender identity. The use of inflammatory language, such as "mutilation," further distorts the conversation and hinders understanding, drawing parallels to the tactics employed in the anti-abortion movement.
The Department of Health and Human Services (HHS) has experienced a period of significant turmoil. In a move that triggered widespread backlash, the Substance Abuse and Mental Health Services Administration (SAMHSA) abruptly canceled funding for hundreds of grantees, representing approximately one-fifth of its budget and impacting crucial programs for addiction, mental health, homelessness, and suicide prevention. However, following furious reactions from Capitol Hill and advocacy groups, the administration reversed these cuts within 24 hours. This rapid reversal suggests either a miscalculation of the potential reaction or a deliberate strategy of creating chaos. The bipartisan nature of the congressional response highlights that these programs align with the administration’s stated priorities, making the initial cuts particularly perplexing.
The shift in societal views on addiction, from a criminal justice issue to a public health concern, has been significant over the past decade. This change is reflected in a bipartisan consensus that views addiction as a health problem affecting all states. The rise of "deaths of despair" and overdose fatalities has prompted increased calls for both funding and compassion from conservatives. The backlash against SAMHSA’s cuts likely included pressure from conservative governors in states heavily impacted by the opioid crisis, who have seen progress in reducing fatal overdoses and increasing access to life-saving medications like Narcan.
Meanwhile, other federal health agencies are also facing instability. Several hundred workers at the National Institute of Occupational Safety and Health (NIOSH), a subagency of the CDC, have reportedly been reinstated following earlier reductions in force (RIF) that occurred nine months prior. At the National Institutes of Health (NIH), the director indicated that Diversity, Equity, and Inclusion (DEI) grants, previously canceled and reinstated by court order, are unlikely to be renewed. Furthermore, a former FDA drug regulator described the "firewall" between political appointees and career drug reviewers as "breached." This continuous churn and uncertainty about leadership and personnel within HHS raise significant questions about the agencies’ ability to function effectively and fulfill their missions. The constant back-and-forth, including administrative leave and lab closures, is not only disruptive to programs and research but also incurs additional costs for taxpayers. The lack of consistent leadership at various levels within these agencies suggests a potential erosion of institutional knowledge and a diminished capacity to execute critical public health functions.
The "Bill of the Month" series, now in its eighth year, continues to highlight the persistent issues within the American medical billing system. Elisabeth Rosenthal, senior contributing editor at KFF Health News and originator of the series, reflects on its enduring relevance. While the series has contributed to positive changes, such as the passage of the No Surprises Act and state-level efforts to regulate facility fees, the fundamental challenges of dubious, infuriating, or inflated medical charges remain. The series has successfully advocated for the write-off of millions of dollars in erroneous bills for individual patients, often triggered by media inquiries. However, the ongoing prevalence of such issues points to a deeply dysfunctional system that leaves millions of Americans burdened by medical debt.
This month’s featured case involves Maxwell Kruzic, who experienced severe abdominal pain after consuming exceptionally spicy chili peppers. His ER visit, initially suspected to be appendicitis, revealed no such condition. After extensive testing, the cause was identified as a reaction to the peppers, which were rated at 2 million Scoville heat units. While Kruzic recovered, the notable aspect of his case was the delay in billing. Nearly two years after his ER visit, he received a bill for just over $2,000, his coinsurance for the $8,000 hospital charge. This "ghost bill" raises questions about the legality and ethics of such late billing practices. The hospital and insurer’s explanations, citing personnel absences and back-end negotiations to determine the service’s value, highlight the complexities of insurance contracts and the potential for hospitals to attempt billing even after significant delays. The lack of a clear statute of limitations on billing for providers, compared to the stricter timelines for insurance claims, creates an asymmetry that can disadvantage patients.
In advice for consumers facing similar situations, it is recommended to consult with one’s insurer to ascertain the terms of the contract regarding late billing. In Kruzic’s case, the hospital eventually waived the bill, acknowledging a mistake in the protracted billing process. However, the potential for hospitals to "try their luck" with late billing underscores the need for greater policy intervention to establish clearer timelines and prevent such practices. Kruzic has since modified his consumption of extremely spicy foods, vowing never to eat scorpion peppers again.
The segment concludes with "extra credit" recommendations from the KFF Health News team. Anna Edney highlights a MedPage Today article addressing concerns about liability following CDC vaccine schedule changes. Alice Miranda Ollstein points to a ProPublica piece on the coordinated efforts to obstruct various sources of fluoride, beyond public water fluoridation. Joanne Kenen shares a thoughtful New Yorker essay reflecting on the realities of emergency room care and compassion. Julie Rovner’s recommendation is a New York Times article detailing the EPA’s decision to cease considering lives saved when setting air pollution rules, a move likely to result in dirtier air and increased health risks.